Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Mar;21(3):152-61. doi: 10.1097/FPC.0b013e3283385a1c. No abstract available.

2.

[Pharmacogenetic criteria of drug-resistant epilepsy].

Oros MM.

Lik Sprava. 2012 Dec;(8):71-4. Ukrainian.

PMID:
23786015
3.

MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion.

Löscher W, Delanty N.

Pharmacogenomics. 2009 May;10(5):711-3. doi: 10.2217/pgs.09.47. No abstract available.

4.

Clinical significance of ABCB1 genotyping in oncology.

Hamidovic A, Hahn K, Kolesar J.

J Oncol Pharm Pract. 2010 Mar;16(1):39-44. doi: 10.1177/1078155209104380. Epub 2009 Apr 28.

5.

Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD, Shi Z, Wu CP, Ashby CR Jr, Akiyama S, Ambudkar SV, Chen ZS, Fu LW.

Biochem Pharmacol. 2009 Aug 15;78(4):355-64. doi: 10.1016/j.bcp.2009.04.023. Epub 2009 May 3.

6.

MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents.

Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ.

Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4.

7.

PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.

Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R, Chen ZS.

Cancer Chemother Pharmacol. 2013 Jul;72(1):189-99. doi: 10.1007/s00280-013-2184-z. Epub 2013 May 15.

PMID:
23673445
8.

Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis.

Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y.

Epilepsia. 2009 Apr;50(4):898-903. doi: 10.1111/j.1528-1167.2008.01858.x. Epub 2008 Oct 24.

9.

Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.

Zhou SF.

Xenobiotica. 2008 Jul;38(7-8):802-32. doi: 10.1080/00498250701867889 . Review.

PMID:
18668431
10.
11.

Multidrug resistance: genes, polymorphisms, biologic effects, reversal and treatment in cancer chemotherapy.

Aragon-Ching JB.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):582. No abstract available.

PMID:
21244347
12.

ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor.

Rajnai Z, Méhn D, Beéry E, Okyar A, Jani M, Tóth GK, Fülöp F, Lévi F, Krajcsi P.

Drug Metab Dispos. 2010 Nov;38(11):2000-6. doi: 10.1124/dmd.110.032805. Epub 2010 Aug 10.

13.

Generating inhibitors of P-glycoprotein: where to, now?

Crowley E, McDevitt CA, Callaghan R.

Methods Mol Biol. 2010;596:405-32. doi: 10.1007/978-1-60761-416-6_18.

PMID:
19949934
14.

Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.

Kanagasabai R, Krishnamurthy K, Druhan LJ, Ilangovan G.

J Biol Chem. 2011 Sep 23;286(38):33289-300. doi: 10.1074/jbc.M111.249102. Epub 2011 Jul 22.

15.

Multidrug resistance in epilepsy: a pharmacogenomic update.

Tate SK, Sisodiya SM.

Expert Opin Pharmacother. 2007 Jul;8(10):1441-9. Review.

PMID:
17661727
16.

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells.

Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW.

Mol Cancer Ther. 2008 Mar;7(3):670-8. doi: 10.1158/1535-7163.MCT-07-0397.

17.

ABCB1 variant provides important leads for pharmacogenetics of epilepsy.

Phani MN, Satyamoorthy K.

J Postgrad Med. 2014 Jul-Sep;60(3):239-40. No abstract available.

PMID:
25272393
18.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O.

Eur J Cancer. 2013 May;49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028. Epub 2013 Feb 17.

PMID:
23422148
19.

Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1.

Crowley E, O'Mara ML, Reynolds C, Tieleman DP, Storm J, Kerr ID, Callaghan R.

Biochemistry. 2009 Jul 7;48(26):6249-58. doi: 10.1021/bi900373x.

20.

Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.

Cancer Res. 2007 Oct 15;67(20):9609-12. Review.

Supplemental Content

Support Center